Buckysomes, liposome-like vesicles comprised of dendritic C60 subunits that self-assemble into unilamellar vesicles, are unique nanovectors that have utility in drug delivery. We have prepared paclitaxel-embedded buckysomes (PEBs) and examined biodistriubition profiles with commercially available formulations of the drug. As compared to Abraxane, an albumin-bound formulation of paclitaxel, PEBs...

Liposomes are spherically shaped phospholipid bilayers that used to encapsulate hydrophilic or lipophilic drugs. To have efficient drug delivery by a liposome, it should be able deliver the specific binding site, where can affect target. However, sometimes, due untimely release, this goal cannot achieved. Therefore, permeation rate of through liposomal membrane is important, as affects drug’s r...

Breast Cancer Treatment In article number 2107550, Wassana Yantasee and co-workers develop polymer-decorated mesoporous silica nanoparticles for HER2-positive breast cancer treatment. This patented versatile platform can co-deliver multiple therapeutic classes to ensure that they reach the target cells at same time fully realize their synergy. Illustrated herein are with three drug cargos: HER2...

Tumor Therapy In article number 2106606, Nan Qin, Tiger H. Tao, and co-workers report a heterogenous silk microneedle patch to spatiotemporally sequentially deliver multiple therapeutic drugs for hemostasis, anti-angiogenesis, apoptosis of brain tumor cells. Drug release kinetics are well-defined by tuning the crosslinking degree applying trigger transcranial NIR-light irradiation. This biodegr...

Until the 1980s, anti-drug education campaigns in UK were rare. This article examines reasons behind a policy shift that led to introduction of mass media drug mid 1980s. It focuses on two campaigns. ‘Heroin Screws You Up’ ran England, and ‘Choose Life Not Drugs’ Scotland. The different tone, with making use fear ‘shock horror’ tactics, whereas attempted deliver more positive health message. wa...

Using nanoparticles to deliver chemotherapeutics offers new opportunities for cancer therapy, but challenges still remain when they are used for the delivery of multiple drugs, especially for the synchronous delivery of hydrophilic and hydrophobic drugs in combination therapies. In this paper, we developed an approach to deliver hydrophilic-hydrophobic anticancer drug pairs by employing magneti...

Hypoxia-inducible factor 1α (HIF1α) has emerged as a promising new target for pancreatic cancer treatment over the past decade. High expression of HIF-1α increases the drug resistance of the current first line chemotherapeutic drug, gemcitabine (Gem). Here we employed biocompatible lipid-polymer hybrid nanoparticles to co-deliver HIF1α siRNA (si-HIF1α) and Gem for pancreatic cancer treatment in...

Combination therapy has been a norm in clinical practice to effectively treat cancer. Besides polytherapy, nowadays, smart and nanobased drug carriers are extensively being explored to deliver drugs according to pathophysiological environment of diseases. In this regard, herein we designed intelligent mesoporous architecture, incorporating both combinational therapy with smart nanotechnology, t...

The potential of transdermal drug delivery systems has been demonstrated in recent years with the approval of several medicines for use by patients who are unable to use conventional dosage routes, like oral administration or injection. To enhance the TDDS (Transdermal Drug Delivery System) potential to include other drug candidates, many researchers have been exploring enhancement approaches t...

Triple negative breast cancer (TNBC) is a difficult to treat disease due to the absence of the three unique receptors estrogen, progesterone and herceptin-2 (HER-2). To improve the current therapy and overcome the resistance of TNBC, there is unmet need to develop an effective targeted therapy. In this regard, one of the logical and economical approaches is to develop a tumor hypoxia-targeting ...